Analyst Ratings For Emergent Biosolutions (NYSE:EBS)
Today, Goldman Sachs Group initiated coverage on Emergent Biosolutions (NYSE:EBS) with a Neutral with a price target of $55.00.
Some recent analyst ratings include
- 1/24/2018-Goldman Sachs Group initiated coverage with a Neutral rating.
- 9/30/2017-Wells Fargo & Co Reiterated Rating of Outperform.
- 1/9/2017-Cowen Reiterated Rating of Hold.
Recent Insider Trading Activity For Emergent Biosolutions (NYSE:EBS)
Emergent Biosolutions (NYSE:EBS) has insider ownership of 16.50% and institutional ownership of 88.53%.
- On 1/2/2018 Daniel Abdun-Nabi, CEO, sold 21,906 with an average share price of $47.91 per share and the total transaction amounting to $1,049,516.46.
- On 12/13/2017 Daniel Abdun-Nabi, CEO, sold 20,000 with an average share price of $45.99 per share and the total transaction amounting to $919,800.00.
- On 12/12/2017 Ronald Richard, Director, sold 23,681 with an average share price of $45.02 per share and the total transaction amounting to $1,066,118.62.
- On 12/7/2017 Zsolt Harsanyi, Director, sold 7,000 with an average share price of $42.47 per share and the total transaction amounting to $297,290.00.
- On 11/29/2017 Fuad El-Hibri, Chairman, sold 47,983 with an average share price of $41.88 per share and the total transaction amounting to $2,009,528.04.
- On 11/14/2017 Fuad El-Hibri, Chairman, sold 40,000 with an average share price of $40.37 per share and the total transaction amounting to $1,614,800.00.
- On 11/7/2017 George A Joulwan, Director, sold 14,251 with an average share price of $41.24 per share and the total transaction amounting to $587,711.24.
Recent Trading Activity for Emergent Biosolutions (NYSE:EBS)
Shares of Emergent Biosolutions closed the previous trading session at 50.48 down -0.34 0.67% with shares trading hands.